Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04430452
Title Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mary Feng, MD

hepatocellular carcinoma



Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.